New FDA-approved drug combo reduces prostate cancer death risk by 40 percent
A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with high-risk recurrent prostate cancer. This combination therapy reduced the risk of death by nearly 40% over eight years, offering a substantial advancement in treatment options.
A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with high-risk recurrent prostate cancer. This combination therapy reduced the risk of death by nearly 40% over eight years, offering a substantial advancement in treatment options.
